U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Unit Dose Services, LLC - 636177 - 12/21/2022
  1. Warning Letters

CLOSEOUT LETTER

Unit Dose Services, LLC MARCS-CMS 636177 —

Reference #:
WL 2310
Product:
Drugs

Recipient:
Recipient Name
Peter Levasseur
Unit Dose Services, LLC

20201 Northeast 16th Place
Miami, FL 33179
United States

Issuing Office:
Center for Drug Evaluation and Research | CDER

United States


Dear Mr. Levasseur:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter # 2310. Based on our evaluation, it appears that you have addressed the violations contained in this warning letter and corrected the data deficiencies. We have received an updated listing SPL with the correct carton label image for your product and an updated labeler code request SPL with the new contact information. Future FDA regulatory activities will further assess the adequacy and sustainability of these corrections. 

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and to continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. 


Sincerely,
/S/
Carolyn E. Becker, JD
Director, Office of Unapproved Drugs & Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research 
U.S. Food and Drug Administration

Back to Top